An upstream regulator analysis indicated that PPARα and XBP1 were the top 2 predicted transcription activators involved in the process of hepatic steatosis induced by OSI-906, whereas pathways related to SREBF2 and lysophosphatidylcholine were identified in the linagliptin-treated group (Supplementary Table S8). Here, SREBF2 is linked to fatty liver disease.